Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

PURPOSE: This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53–MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. PATIENTS AND METHODS: Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12.5–350 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Eytan M., DeAngelo, Daniel J., Chromik, Jörg, Chatterjee, Manik, Bauer, Sebastian, Lin, Chia-Chi, Suarez, Cristina, de Vos, Filip, Steeghs, Neeltje, Cassier, Philippe A., Tai, David, Kiladjian, Jean-Jacques, Yamamoto, Noboru, Mous, Rogier, Esteve, Jordi, Minami, Hironobu, Ferretti, Stephane, Guerreiro, Nelson, Meille, Christophe, Radhakrishnan, Rajkumar, Pereira, Bernard, Mariconti, Luisa, Halilovic, Ensar, Fabre, Claire, Carpio, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377734/
https://www.ncbi.nlm.nih.gov/pubmed/34862243
http://dx.doi.org/10.1158/1078-0432.CCR-21-1295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377734/
https://www.ncbi.nlm.nih.gov/pubmed/34862243
http://dx.doi.org/10.1158/1078-0432.CCR-21-1295

Ejemplares similares